SARS-CoV-2 infection in patients with autoimmune hepatitis.

Marjot, Thomas, Buescher, Gustav, Sebode, Marcial, Barnes, Eleanor, Barritt, Alfred S, Armstrong, Matthew J, Baldelli, Luke, Kennedy, James, Mercer, Carolyn, Ozga, Ann-Kathrin, Casar, Christian and Schramm, Christoph (2021) SARS-CoV-2 infection in patients with autoimmune hepatitis. Journal of hepatology. ISSN 1600-0641. (In Press) This article is available to all UHB staff and students via ASK Discovery tool http://tinyurl.com/z795c8c by using their UHB Athens login IDs

[img]
Preview
Text (PDF file format)
JOH.pdf - Accepted Version
Available under License Creative Commons Attribution 4.0.

Download (7MB) | Preview
Official URL: https://www.journal-of-hepatology.eu/article/S0168...

Abstract

BACKGROUND

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 2019 (COVID-19) continues to have a devastating impact across the globe. However, little is known about the disease course in patients with autoimmune hepatitis (AIH).

METHODS

Data for patients with AIH and SARS-CoV-2 infection were combined from three international reporting registries and outcomes were compared to those with chronic liver disease of other aetiology (non-AIH CLD) and to patients without liver disease (non-CLD).

RESULTS

Between 25 March and 24 October 2020, data were collected for 932 patients with CLD and SARS-CoV-2 infection including 70 with autoimmune hepatitis (AIH). Fifty-eight (83%) of AIH patients were taking one or more immunosuppressive drug. There were no differences in rates of major outcomes between AIH and non-AIH CLD including hospitalization (76% vs 85%; p= 0.06), ICU admission (29% vs. 23%; p=0.240), and death (23% vs. 20%; p=0.643). Factors associated with death within the AIH cohort included age (OR 2.16/10 years; 1.07-3.81), Child-Turcotte-Pugh (CTP) class B (OR 42.48; 4.40-409.53), and CTP-C cirrhosis (OR 69.30; 2.83-1694.50), but not use of immunosuppression. Propensity score matched (PSM) analysis comparing AIH with non-AIH CLD demonstrated no increased risk adverse outcomes including death (+3.2%; -9.2%-15.7%). PSM analysis of AIH versus non-CLD patients (n=769) demonstrated increased risk of hospitalization with AIH (+18.4%; 5.6-31.2%), but equivalent risk of all other outcomes including death (+3.2%; -9.1%-15.6%).

CONCLUSION

AIH patients were not at increased risk of adverse outcomes despite immunosuppressive treatment compared to other causes of CLD and to matched cases without liver disease.

Item Type: Article
Additional Information: This article is available to all UHB staff and students via ASK Discovery tool http://tinyurl.com/z795c8c by using their UHB Athens login IDs
Subjects: WC Communicabable diseases
WI Digestive system. Gastroenterology
Divisions: Planned IP Care > Gastroentrology
Related URLs:
Depositing User: Mrs Yolande Brookes
Date Deposited: 29 Jan 2021 15:31
Last Modified: 29 Jan 2021 15:35
URI: http://www.repository.uhblibrary.co.uk/id/eprint/3923

Actions (login required)

View Item View Item